A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
Status:
Terminated
Trial end date:
2016-01-14
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the preliminary anti-tumor activity and tolerability of
PF-03084014 when administered as a single agent in the treatment of patients with advanced
triple receptor-negative breast cancer (mTNBC) harboring genomic alterations in Notch
receptors (NA+), and in a smaller subset of mTNBC patients whose tumor tests negative for
genomic alterations in Notch receptors (NA-)